New monthly shot could keep severe asthma patients out of the ER

NCT ID NCT06705764

Recruiting now Disease control Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests whether a monthly injection called Tezepelumab can help adults with severe asthma avoid repeated emergency room visits and asthma attacks. One hundred participants will receive either the drug or a placebo for 90 days, followed by an open-label extension. The goal is to see if starting this medication in the ER can reduce the need for steroids and hospital stays.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tezepelumab (a monthly injection)
What this could lead to: If it works, this could offer a new way to prevent severe asthma attacks and reduce emergency room visits for adults with hard-to-control asthma.
What could go wrong: This is a relatively small, early-phase trial (100 participants) and results may not apply to all asthma patients. The drug is already approved, but its effectiveness in an emergency setting is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE ASTHMA

Contacts and locations

Locations

Sturgeon Community Hospital
NOT_YET_RECRUITING

St. Albert, Alberta, T8N6C4, Canada
University of Alberta
RECRUITING

Edmonton, Alberta, T6G 2G3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.